A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations

Genetic markers like APOE ε4 marked a significant turning point in the quest for a blood test to detect Alzheimer's disease (AD). More recently, researchers have been striving to find various biomarker modalities to enhance their predictive capabilities. Researchers from the United Kingdom have undertaken an exploration of the trends and challenges within the realm of AD blood biomarker research. To introduce these promising biomarkers towards clinical applicability, it is imperative that they undergo rigorous testing by independent researchers.
The widespread utilization of smartphones and wearable devices offers a unique opportunity to establish a more objective, continuous, and all-encompassing phenotypic profile. This profile spans the entire spectrum of the disease, from those at risk and early diagnosis to post-diagnosis engagement, and self-management. This wealth of data holds the potential to expand ongoing blood biomarker studies and clinical trials. The domain of AD blood biomarkers include genetic and protein markers, metabolites, gene expression markers, as well as various combinations. The burning question remains: will a clinically valuable blood test for AD be available? It is, without a doubt, too early to definitively answer that query. However, the odds of success are significantly improved if there is a concerted effort to enhance the design, analysis, and reporting of studies in this field.